Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study

International Journal of Lung Cancer · Elsevier

Аннотация

Publication date: September 2026 Source: International Journal of Lung Cancer, Volume 1, Issue 3 Author(s): Yutaka Fujiwara, Motohiro Tamiya, Eisaku Miyauchi, Yoshitaka Kawa, Noriko Yanagitani, Yuki Takeyasu, Ai Murata, Ikuyo Kawabata, Tomoyo Oguri, Makoto Nishio

Читать у издателя →

Похожие статьи